Stocksigma LogoStocksigma Logo

Rubicon Research Receives Single Form 483 Observation for Satara Facility

The US FDA conducted an unannounced inspection at Rubicon Research鈥檚 manufacturing facility in Satara, Maharashtra, from 5th Oct'26 to 9th Oct'26

Rubicon Research Receives Single Form 483 Observation for Satara Facility

Rubicon Research Ltd 路 Others (Uncategorized) 路 10 Oct 2026, 1:45 am

Rubicon Research Receives Single Form 483 Observation for Satara Facility The US FDA conducted an unannounced inspection at Rubicon Research鈥檚 manufacturing facility in Satara, Maharashtra, from 5th Oct'26 to 9th Oct'26. The audit concluded with the issuance of a Form 483 with one observation, which is procedural and does not involve data integrity. This marks the company's third unannounced US FDA inspection in FY27, following audits at its Toronto R&D site in Apr'26 and Pithampur facility in Jul'26. Rubicon remains confident in resolving the observation with the regulator promptly.

Original exchange filing (PDF)

More announcements from Rubicon Research Ltd

All Rubicon Research Ltd announcements